OKYO Pharma (OKYO) Competitors $2.25 -0.02 (-0.88%) Closing price 04:00 PM EasternExtended Trading$2.22 -0.02 (-1.11%) As of 06:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock OKYO vs. ADCT, ALDX, FULC, CGC, BNTC, CTMX, CADL, AMRN, LRMR, and DRUGShould you be buying OKYO Pharma stock or one of its competitors? The main competitors of OKYO Pharma include ADC Therapeutics (ADCT), Aldeyra Therapeutics (ALDX), Fulcrum Therapeutics (FULC), Canopy Growth (CGC), Benitec Biopharma (BNTC), CytomX Therapeutics (CTMX), Candel Therapeutics (CADL), Amarin (AMRN), Larimar Therapeutics (LRMR), and Bright Minds Biosciences (DRUG). These companies are all part of the "pharmaceutical products" industry. OKYO Pharma vs. Its Competitors ADC Therapeutics Aldeyra Therapeutics Fulcrum Therapeutics Canopy Growth Benitec Biopharma CytomX Therapeutics Candel Therapeutics Amarin Larimar Therapeutics Bright Minds Biosciences OKYO Pharma (NASDAQ:OKYO) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, earnings, dividends, profitability, valuation, risk, media sentiment and analyst recommendations. Which has more risk & volatility, OKYO or ADCT? OKYO Pharma has a beta of -0.1, indicating that its share price is 110% less volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 2, indicating that its share price is 100% more volatile than the S&P 500. Is OKYO or ADCT more profitable? OKYO Pharma has a net margin of 0.00% compared to ADC Therapeutics' net margin of -220.00%. Company Net Margins Return on Equity Return on Assets OKYO PharmaN/A N/A N/A ADC Therapeutics -220.00%N/A -53.73% Do institutionals & insiders hold more shares of OKYO or ADCT? 3.0% of OKYO Pharma shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 40.5% of OKYO Pharma shares are held by insiders. Comparatively, 5.4% of ADC Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term. Does the media prefer OKYO or ADCT? In the previous week, ADC Therapeutics had 1 more articles in the media than OKYO Pharma. MarketBeat recorded 3 mentions for ADC Therapeutics and 2 mentions for OKYO Pharma. OKYO Pharma's average media sentiment score of 0.96 beat ADC Therapeutics' score of 0.59 indicating that OKYO Pharma is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment OKYO Pharma 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive ADC Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Which has higher earnings & valuation, OKYO or ADCT? OKYO Pharma has higher earnings, but lower revenue than ADC Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioOKYO PharmaN/AN/A-$4.71MN/AN/AADC Therapeutics$70.84M5.41-$157.85M-$1.57-2.17 Do analysts rate OKYO or ADCT? OKYO Pharma presently has a consensus price target of $7.00, suggesting a potential upside of 211.11%. ADC Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 127.47%. Given OKYO Pharma's higher possible upside, equities research analysts plainly believe OKYO Pharma is more favorable than ADC Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score OKYO Pharma 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00ADC Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 0 Strong Buy rating(s) 3.00 SummaryOKYO Pharma beats ADC Therapeutics on 6 of the 11 factors compared between the two stocks. Get OKYO Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for OKYO and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding OKYO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart OKYO vs. The Competition Export to ExcelMetricOKYO PharmaMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$85.38M$3.13B$5.75B$9.85BDividend YieldN/A2.28%6.67%4.51%P/E RatioN/A20.8978.4326.42Price / SalesN/A458.96546.94119.09Price / CashN/A44.5237.0558.92Price / Book-14.069.9310.916.06Net Income-$4.71M-$53.38M$3.29B$266.28M7 Day Performance-1.32%0.05%0.01%-0.76%1 Month Performance-27.88%7.08%7.06%3.83%1 Year Performance104.55%11.92%50.09%24.39% OKYO Pharma Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)OKYOOKYO Pharma3.2374 of 5 stars$2.25-0.9%$7.00+211.1%+97.4%$85.38MN/A0.007News CoverageShort Interest ↓ADCTADC Therapeutics2.7382 of 5 stars$3.17+2.6%$7.75+144.5%+20.3%$356.62M$77.25M-2.02310Short Interest ↓ALDXAldeyra Therapeutics2.5007 of 5 stars$5.89+2.1%$9.50+61.3%+0.7%$352.81MN/A-6.9310News CoverageFULCFulcrum Therapeutics1.0039 of 5 stars$6.52+1.7%$7.57+16.1%-19.5%$352.68MN/A-5.34100News CoverageHigh Trading VolumeCGCCanopy Growth1.4385 of 5 stars$1.47+2.1%N/A-72.2%$352.58M$274.92M-0.493,150Positive NewsShort Interest ↓High Trading VolumeBNTCBenitec Biopharma1.6686 of 5 stars$12.76-3.4%$26.00+103.8%+54.9%$334.95M$80K-8.4520News CoverageCTMXCytomX Therapeutics4.2525 of 5 stars$2.03+1.5%$5.75+183.3%+89.3%$334.77M$138.10M3.63170CADLCandel Therapeutics2.0329 of 5 stars$5.96+4.4%$22.00+269.1%-19.0%$327.20M$120K-8.6460News CoverageAnalyst DowngradeAMRNAmarin0.6407 of 5 stars$15.54+1.0%$12.00-22.8%+20.2%$321.79M$219.36M-4.23360LRMRLarimar Therapeutics3.1184 of 5 stars$3.87+4.0%$18.43+376.2%-43.1%$320.35MN/A-2.4830Positive NewsDRUGBright Minds Biosciences3.0322 of 5 stars$44.77+7.4%$83.25+86.0%+3,888.0%$315.18MN/A-48.14N/ANews CoveragePositive NewsGap Up Related Companies and Tools Related Companies ADCT Alternatives ALDX Alternatives FULC Alternatives CGC Alternatives BNTC Alternatives CTMX Alternatives CADL Alternatives AMRN Alternatives LRMR Alternatives DRUG Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:OKYO) was last updated on 9/4/2025 by MarketBeat.com Staff From Our PartnersThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredTrump’s national nightmare is hereThe headlines are shocking: Washington has taken a $10 billion stake in one of America’s biggest chipmakers — ...Porter & Company | SponsoredWall Street Legend Names #1 ‘Hidden’ AI Stock50-year Wall Street legend says to forget NVDA. For the biggest potential gains, it's time to move your money ...Chaikin Analytics | SponsoredNVIDIA's Worst Nightmare?$2 TRILLION Quantum Gold Rush While everyone fights over expensive AI stocks... McKinsey just revealed the ...The Oxford Club | SponsoredThe man running the U.S. dollar… is hoarding goldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | Sponsored2013 Bitcoin miner reveals his trading system (free)While everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding OKYO Pharma Limited Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share OKYO Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
